Abstract
Abstract
Background
Prevalence of hepatitis C virus infection in patients with renal diseases is higher compared to the general population. FDA has approved ombitasvir/paritaprevir/ ritonavir for the treatment of patients with severe renal disease. This study aimed to evaluate the efficacy and safety of ombitasvir/paritaprevir/ritonavir with or without ribavirin in treatment of chronic hepatitis C Egyptian hemodialysis patients to compare it with the same treatment result in chronic hepatitis C Egyptian patients with normal renal functions. This case-control study was conducted on one hundred patients with confirmed diagnosis of HCV-positive infection at the Center of National Committee for Control of Viral Hepatitis [NCCVH] at Ain Shams University Hospital. Patients were divided into two groups: group I (control group) with 50 chronic hepatitis C virus patients with normal renal functions and group II (Case Group) with 50 chronic hepatitis C virus hemodialysis patients.
Results
95.1% of prevalent hemodialysis patients achieved sustained virological response (SVR), while 100% of patients with normal kidney functions achieved sustained virological response. Most common side effects were hemoglobin drop, gastrointestinal disturbance, severe fatigue, and itching.
Conclusion
Ombitasvir, paritaprevir, and ritonavir are considered a safe and effective in treatment in HCV infection in patients on regular hemodialysis as in chronic hepatitis C virus infection patients with normal kidney functions.
Publisher
Springer Science and Business Media LLC
Reference19 articles.
1. Gower E, Estes C, Blach S et al (2014) Global epidemiology and genotype distribution of the hepatitis C virus infection. Journal of Hepatology 61(1):S45–S57. https://doi.org/10.1016/j.jhep.2014.07.027
2. Gomaa A, Allam N, Elsharkway A et al (2017) Hepatitis C infection in Egypt: prevalence, impact and management strategies. Hepatic Medicine: Evidence and Research 9:17. https://doi.org/10.2147/HMER.S113681
3. McConachie SM, Wilhelm SM, Kale-Pradhan PB (2016) New direct-acting antivirals in hepatitis C therapy: a review of sofosbuvir, ledipasvir, daclatasvir, simeprevir, paritaprevir, ombitasvir and dasabuvir. Expert Rev Clin Pharmacol 9(2):287–302
4. Feld JJ, Kowdley KV, Coakley E et al (2014) Treatment of HCV with ABT-450/r–ombitasvir and dasabuvir with ribavirin. N Engl J Med 370(17):1594–1603. https://doi.org/10.1056/NEJMoa1315722
5. American Association for the study of Liver Disease/Infectious Disease Society of America/ International Antiviral Society (2016) Recommendations for testing, managing, and treating hepatitis C virus.
Cited by
1 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献